Neogen Corporation

Neogen is a mid-cap, consumables-heavy diagnostics company. Its core is food-safety testing, and it ranks among the larger focused suppliers globally. The 2022 Reverse Morris Trust combination with 3M's Food Safety Division brought in the Petrifilm indicator-testing franchise, Clean-Trace and the Molecular Detection System. That deal turned a roughly $0.5bn niche player into an $870m-revenue platform in which Food Safety accounts for about 74% of sales.

The integration then proved costly. It produced $1.06bn of goodwill impairments in FY2025, supply disruptions, material weaknesses in internal control, securities litigation, and a full leadership turnover under CEO Mike Nassif, who arrived in August 2025.

FY2026 was explicitly a "stabilisation" year. Management simplified the portfolio by selling Cleaners & Disinfectants and agreeing to sell Genomics, cut costs, and restored core growth to 4.3% in Q4. The investment case now depends on four things:

• bringing Petrifilm manufacturing in-house in Lansing;

• deleveraging net debt from about 3.4x adjusted EBITDA to below 3x;

• reinvigorating R&D;

• making progress toward a stated long-term adjusted EBITDA margin of about 30%, against 20.4% in FY2026.

Company's own description (paraphrased from FY2026 10-K, Item 1)

Neogen and its subsidiaries develop, manufacture and market products and services for food and animal safety.

Food Safety segment. This consists mainly of diagnostic test kits and complementary products such as culture media. They are sold to food and animal-feed producers and processors, laboratories and regulators. Customers use them to detect:

• foodborne pathogens and spoilage organisms;

• natural toxins (mycotoxins) and food allergens;

• ruminant by-products and sanitation indicators.

Most kits are single-use consumables built on culture, immunoassay and nucleic-acid detection. They rely on proprietary antibodies and RNA/DNA methods. The segment also includes software (Neogen Analytics) for aggregating and trending test results.

Animal Safety segment. This develops, makes and distributes:

• veterinary instruments, pharmaceuticals, vaccines, topicals and parasiticides;

• diagnostics, rodent control and insect control products;

• genomics testing services (pending sale to Zoetis).

It also sells drug-detection assays to animal, workplace and forensic toxicology markets.

Mission and stated growth strategy. The 10-K describes the aim of being the leading company in global food and animal safety and security. The stated growth strategy has four elements:

1. increasing sales of existing products;

2. introducing innovative products and services;

3. growing international sales;

4. making acquisitions and strategic alliances.

Revenue model

Source: Q4 FY2026 8-K, condensed statement of operations.

How revenue is earned:

Product sales (88% of FY2026 revenue): These are dominated by recurring consumables: Petrifilm plates, culture media, test kits, swabs and sample-collection devices, rodenticides and veterinary disposables. Instruments and readers (Petrifilm Plate Reader Advanced, MDS, AccuPoint and Clean-Trace luminometers, Soleris) act as the "razor" that pulls through consumable demand. Many readers are built by third-party contract manufacturers to Neogen's specifications.

Services (12%): These are mostly fee-per-sample genomics testing, run through GeneSeek, Igenity and GGP-branded genotyping. They will largely leave the group when the Genomics sale to Zoetis closes. Neogen Analytics is a SaaS offering whose revenue is not separately disclosed and appears immaterial.

Licensing: Neogen is a net payer of royalties. It paid royalties of $1.9m in FY2026, $1.6m in FY2025 and $3.3m in FY2024, at typical rates of 2–10% of related product revenue. These relate mainly to allergen and pathogen technologies (FY2026 10-K). Out-licensing revenue is not disclosed.

Channels: Sales go directly and through distributors. The proxy states that online orders represent about 40% of Food Safety revenue (DEF 14A 2026, CEO letter).

Value-chain position

Neogen is a developer-manufacturer of diagnostic consumables and animal-safety products. It sits between raw-material and component suppliers (antibodies, media components, films, plastics, actives) and end users: food processors, contract laboratories, veterinarians and livestock producers.

It is vertically integrated in:

• antibody purification;

• media blending;

• molecular assay manufacture (Lansing);

• sample collection and animal-health kits (Lexington, Kentucky);

• Clean-Trace (Bridgend, Wales);

• Megazyme enzymes (Bray, Ireland).

Petrifilm is still made by 3M under a transition contract-manufacturing arrangement in US and Polish 3M plants. A multi-quarter move to Neogen's Lansing site begins in November 2026. European diagnostics distribution runs through a third-party facility in the Netherlands.

Customer types and end-markets (FY2026 10-K)

Food Safety customers include:

• milling and grain (elevators, feed mills, pet food, grain inspection);

• meat and poultry, including the USDA Food Safety and Inspection Service;

• ready-to-eat foods, fruit and vegetables, seafood, dairy, beverage and water;

• healthcare, traditional culture-media users (pharma, cosmetics, veterinary vaccines), food service and retail grocery, and dietary supplements.

Animal Safety customers include:

• companion-animal veterinarians;

• livestock producers and breed associations;

• farm-and-ranch retailers;

• breeding and genetics companies;

• diagnostic labs and universities;

• distributors, other manufacturers and government agencies.

No customer or individual foreign country contributed 10% or more of revenue in FY2024 to FY2026.

Independent characterisation

Neogen is best understood as a "food-safety consumables franchise attached to a sub-scale animal-safety distribution business".

Food Safety is the economic engine. It is $641m of FY2026 revenue (74%). The 3M-derived Indicator Testing & Culture Media category alone is $333m and grew 6.6% in FY2026.

Animal Safety is lower-margin and more cyclical. It is $229m (26%) and depends on distribution, being exposed to livestock economics and seasonal pest pressure. After the Genomics sale, the remaining Animal Safety business is roughly $140m of revenue on an FY2026 base (derived: $229.3m less $67.6m of Animal-segment Genomics, less about $20m of Cleaners & Disinfectants revenue that has already gone). That raises a strategic question about whether the rest of the segment is core, which management has not addressed publicly.

The 3M deal transformed scale but not profitability.

• Adjusted EBITDA margin fell from 25.0% in FY2023 to 20.4% in FY2026.

• GAAP results have been negative every year since the deal closed.

• Goodwill has roughly halved through impairments.

Stated strategy (DEF 14A CEO letter, 21 Aug 2026; Q4 FY2026 release and call)

The CEO letter frames FY2026 as a turning point and FY2027 as a year of disciplined execution, aimed at strengthening Neogen's position as a global food-safety category leader. It sets out three priorities.

1. Building a world-class commercial engine.

   • New global go-to-market and enterprise-wide solutions-based selling model.

   • Sales resources realigned to priority markets, products and customers.

   • Unified selling standards to drive portfolio selling across tests, analytics, training and technical support.

   • Enterprise engagement at top accounts.

   • Digital and e-commerce investment; online orders are about 40% of Food Safety revenue.

2. Accelerating innovation.

   • R&D spending planned to rise about 50% in FY2027.

   • Focus areas: extending the proprietary Petrifilm platform, the digital analytics ecosystem, and differentiated testing and diagnostics.

   • Selective partnering and in-licensing.

   • Management states development cycles of 18–24 months, so meaningful revenue contribution is expected from FY2029.

3. Driving operational excellence.

   • FY2026 results: inventory down 24%, on-time delivery up 40%.

   • Complete the Petrifilm manufacturing transition, worth 200–300 bps of margin on the product.

   • "Additive technology and improved process" for efficiency.

Initiatives in the last 24 months

Medium-term financial guidance

Launch years and pricing are generally not publicly disclosed. Neogen sells mainly on purchase orders and distributor price lists. "Legacy 3M" marks products acquired with 3M FSD on 1 Sep 2022.

Food Safety segment

Animal Safety segment

--